We’ve all heard of Health Insurance companies refusing coverage in urgent situations. But this example shows how they can also cheat people in less dramatic ways, making profits with less obvious cheating that is difficult to resolve.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
Why is the FDA approving questionable drugs?
The FDA approved an expensive antidepressant Exxua, despite questionable evidence. Dr. Diana Zuckerman explains why this decision could be harmful for patients—and for all of us.
Read More »Should you get a blood test to predict future Alzheimer’s Disease?
Blood tests for Alzheimer’s disease are being promoted to people who may not need them. Before you get tested, here’s what you should know.
Read More »Should Mammograms Start at Age 30?
Watch Dr. Diana Zuckerman explain why earlier isn’t always better when it comes to breast cancer screening.
Read More »NCHR Written Comment on HHS National Plan To Address Alzheimer’s Disease
August 14, 2026: In response to a request for public comments, NCHR urged HHS to strengthen the ‘National Plan to Address Alzheimer’s Disease’ by improving research that directly informs patient care, treatment decisions, and quality of life for people living with AD/ADRD. We recommend requiring NIH to immediately analyze CMS registry data on Leqembi and Kisunla, and require the other anti-amyloid registries to make data available to HHS for NIA and NINDS to analyze the data and make it public. NCHR also called for stronger oversight of potentially deadly antipsychotic medications used for dementia patients and greater support for patients, families, and caregivers.
Read More »